Durable Polymer Everolimus Eluting Stents

The durable polymer everolimus eluting stents of the Xience and Promus families have become the benchmark of safety and efficacy in the drug eluting stent field. Building on the benefits of first-generation DES, the second-generation DP-EES stents reduced incidence of early restenosis and early stent failure by making improvements to the stent platform, polymer and delivered drug. The Xience and Promus families are characterised by the use of thinner cobalt-chromium or platinum-chromium struts, non-resorbable polymers and by elution of the mTOR inhibitor Everolimus. A robust body of clinical trial evidence has established their superiority over previous BMS and DES and have established these stent families as the gold standard drug-eluting stents with low rates of target vessel failure, target lesion revascularisation and stent thrombosis.